U.S. market Closed. Opens in 7 hours 52 minutes

URGN | UroGen Pharma Ltd. Stock Financials Income Statements Annual

(Stock Exchange: NASDAQ)
*Sign In to persist settings
Financial Year End2023-12-312022-12-312021-12-312020-12-312019-12-312018-12-312017-12-312016-12-312015-12-31
Revenue82.71M64.36M48.04M11.80M18.00K1.13M8.16M17.53MN/A
Cost of Revenue9.36M7.65M5.16M1.01MN/A1.80M600.00K28.00KN/A
Gross Profit73.35M56.70M42.88M10.79M18.00K-675.00K7.56M17.50MN/A
Operating Expenses138.89M135.74M135.18M137.53M109.50M76.50M27.51M16.70MN/A
Selling, General & Admin93.27M82.84M87.53M90.22M60.20M39.57M8.81M6.42M1.90M
Research & Development45.61M52.91M47.64M47.31M49.30M36.93M18.70M10.29M10.52M
Other Operating Expenses838.00K72.00KN/AN/A-284.00KN/AN/AN/AN/A
Operating Income-65.54M-79.04M-92.29M-126.74M-109.48M-77.18M-19.95M798.00K-12.41M
Other Expenses / Income-32.79M-28.99M-17.08M1.63M4.33M-100.00K-31.00K-2.74M-279.00K
Before Tax Income-98.32M-108.03M-109.37M-125.11M-105.15M-75.53M-19.98M-1.94M-12.69M
Income Tax Expenses3.92M1.14M1.45M3.37M-4.62M125.00K19.00KN/AN/A
Net Income-102.24M-109.16M-110.82M-128.48M-100.53M-75.66M-20.00M-1.94M-12.69M
Interest Expenses36.27M8.44M17.44M357.00K-4.33MN/AN/AN/AN/A
Basic Shares Outstanding28.83M22.81M22.35M21.78M20.53M15.75M9.72M11.97M11.97M
Diluted Shares Outstanding28.83M22.81M22.35M21.78M20.53M15.75M9.72M11.97M11.97M
EBITDA-63.83M-78.03M-75.00M-126.74M-108.15M-77.18M-19.77M-1.73M-12.30M
EBITDA Margin-77.17%-121.25%-156.12%-1,074.15%-600,855.56%-6,842.20%-242.39%-9.86%0.00%
EBIT-62.06M-99.59M-91.93M-124.75M-109.48M-75.53M-19.98M-1.94M-12.69M
EBIT Margin-75.03%-154.75%-191.35%-1,057.32%-608,211.11%-6,696.10%-244.93%-11.07%0.00%
Financial Year End2023-12-312022-12-312021-12-312020-12-312019-12-312018-12-312017-12-312016-12-312015-12-31
An error has occurred. This application may no longer respond until reloaded. Reload 🗙